Zolgensma is a gene therapy that treats spinal muscular atrophy in infants and will cost $2,125,000. Novartis will allow purchasers of the drug to make five annual payments of $425,000. Golly gee, how magnanimous of Novartis! Maybe in a few years there will be a generic equivalent that will cost only one million dollars.

FDA approves Zolgensma, the nation's most expensive drug